Prima BioMed Ltd
IMMP Healthcare Biotechnology
Prima BioMed Ltd’s revenue for fiscal 2026 (year ended June 2026) was $16.4 million, up 145.2% from fiscal 2025. Revenue growth for three consecutive years.
Follow IMMP
Prima BioMed Ltd (IMMP) Altman Z-score
Prima BioMed Ltd's Altman Z-score for fiscal 2026 is −10.45, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2026 | −10.45 | (7.17) |
| FY2025 | −3.28 | (1.96) |
| FY2024 | −1.32 | 0.98 |
| FY2023 | −2.30 | 0.94 |
| FY2022 | −3.23 | 0.21 |
| FY2021 | −3.45 | 4.49 |
| FY2020 | −7.94 | 1.65 |
| FY2019 | −9.59 | (2.45) |
| FY2018 | −7.14 | 2.24 |
| FY2017 | −9.38 | 1.68 |
How fiscal 2026’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.80 | — | 0.96 | |
| Retained earnings / total assets | (6.25) | — | −8.76 | |
| EBIT / total assets | (0.93) | — | −3.07 | |
| Market value of equity / total liabilities | 0.21 | — | 0.13 | |
| Sales / total assets | 0.29 | — | 0.29 | |
| Altman Z-score | Distress zone | −10.45 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −18.43 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| EVAX Evaxion A/S - Sponsored ADR compare | −4.5× |
| IMMP Prima BioMed Ltd | −10.5× |
| MCRB Seres Therapeutics, Inc. compare | −11.0× |
| BYSI BeyondSpring Inc. compare | −12.5× |
| ABVC ABVC BioPharma, Inc. compare | −14.9× |
| ESLA Estrella Immunopharma, Inc. compare | — |
| PLRZ Polyrizon Ltd. compare | — |
| CNTX Context Therapeutics Inc. compare | — |
| CYAD Celyad SA compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets